Loading provider…
Loading provider…
Internal Medicine Physician in La Jolla, CA
NPI: 1306861950Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D. Thomas's Phone Numberphone_androidMobile
Get M.D. Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
1980 - 2026
CA State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology
Harvard Medical School
hms.harvard.edu
Medical School
Until 1979
Stanford Health Care-Sponsored Stanford University
Fellowship • Hematology
1982 - 1984
Residency • Internal Medicine
1979 - 1981
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Authors: Emma Young, Daniel Noerenberg, Larry Mansouri, Viktor Ljungström, Mareike Frick, La. Sutton, Stuart Blakemore, Joel Galan-Sousa, Karla Plevová, Panagiotis Baliakas, Davide Rossi, Ruth Clifford, Damien Roos-Weil, Veronika Navrkalová, Bernd Dörken, Clemens A. Schmitt, Karin E. Smedby, Gunnar Juliusson, Brian Giacopelli, James S. Blachly, C. Belessi, Panagiotis Panagiotidis, Nicholas Chiorazzi, Frederic Davi, Anthonie Willem Langerak, David Oscier, Anna Schuh, Gianluca Gaidano, Paolo Ghia, Wei Xu, Lei Fan, Olivier A. Bernard, Florence Nguyen-Khac, Laura Z. Rassenti, Jianyong Li, Thomas J. Kipps, Kostas Stamatopoulos, Šárka Pospíšilová, Thorsten Zenz, Christopher C. Oakes, Jonathan C. Strefford, Richard Rosenquist, Frederik Damm
Publication Date: 2017-07
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
Authors: Jan Burger, Susan O'Brien, Ian Flinn, Michael Keating, Ronald Dubowy, Nicole Lamanna, Siddhartha Mitra, Andrew Zelenetz, Langdon Miller
Publication Date: 2015-12
Lead Sponsor: University of California, San Diego
Intervention / Treatment: DRUG: lenalidomide, DRUG: Obinutuzumab, DRUG: HDMP
Lead Sponsor: Gilead Sciences
Intervention / Treatment: DRUG: Placebo, DRUG: Rituximab, DRUG: Bendamustine, DRUG: Idelalisib
Lead Sponsor: Thomas Kipps
Collaborators: Bayer
Intervention / Treatment: DRUG: Sorafenib